Polycystic Ovarian Syndrome Women with NAFLD and Obstructive Sleeping Apnea: Program of Lifestyle Changes

What this Trial Is About

This research focuses on obese women aged 30 to 40 years who have polycystic ovarian syndrome (PCOS), obstructive sleeping apnea (OSA), and fatty liver disease (NAFLD). The study aims to explore how lifestyle changes, along with medication, affect these conditions in women with these health challenges. The trial is randomized and single-blind, conducted by Cairo University to better understand treatment approaches for this group. Participants will be assigned to one of two groups of twenty obese women each. The study group will take metformin tablets three times daily, follow a low-calorie diet, and engage in daily 30-minute walking for eight weeks. The control group will also take metformin three times daily and follow the same low-calorie diet for eight weeks but without the walking exercise. These interventions are being evaluated to see their impact on liver health and related symptoms. Throughout the eight weeks, researchers will monitor various health measures including blood tests for liver enzymes and hormones, body measurements like neck and waist circumference, body mass index, and sleep quality assessments. The primary outcome is the level of aspartate transaminase in the blood after eight weeks. Secondary outcomes include other liver enzymes, lipid levels, hormone ratios, apnea index, and sleepiness scale. This comprehensive monitoring helps understand how these treatments affect the participants' overall health.

Lifestyle Changes in PCOS with OSA and NAFLD